Short Report

You have full text access to this OnlineOpen article

CHEK2 1100delC is not a risk factor for male breast cancer population

  1. Kirsi Syrjäkoski1,
  2. Tuula Kuukasjärvi2,†,*,
  3. Anssi Auvinen3,
  4. Olli-P Kallioniemi1

Article first published online: 21 OCT 2003

DOI: 10.1002/ijc.11384

Issue

International Journal of Cancer

International Journal of Cancer

Volume 108, Issue 3, pages 475–476, 20 January 2004

Additional Information

How to Cite

Syrjäkoski, K., Kuukasjärvi, T., Auvinen, A. and Kallioniemi, O.-P. (2004), CHEK2 1100delC is not a risk factor for male breast cancer population. Int. J. Cancer, 108: 475–476. doi: 10.1002/ijc.11384

Author Information

  1. 1

    Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland

  2. 2

    Department of Pathology, Tampere University Hospital, Tampere, Finland

  3. 3

    Tampere School of Public Health, University of Tampere, Tampere, Finland

  1. †

    Fax: +358-3-247 5503

*Department of Pathology, Tampere University Hospital, P.O. Box 2000, FIN-33521 Tampere, Finland

Publication History

  1. Issue published online: 21 NOV 2003
  2. Article first published online: 21 OCT 2003
  3. Manuscript Accepted: 5 DEC 2002
  4. Manuscript Received: 8 NOV 2002

Funded by

  • Research Fund of Tampere University Hospital

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (50K)

REFERENCES

  • 1
    Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B, Casey G, Ponder BA, Anton-Culver H. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997; 60: 313–9.
  • 2
    Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, Peng Y, Bogden B, Chen Q, Neuhausen S, Shattuck-Eidens D, Godwin AK, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996; 13: 123–5.
  • 3
    Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996; 13: 117–9.
  • 4
    Syrjäkoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, Holli K, Blomqvist C, Kallioniemi OP, Kainu T, Nevanlinna H. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2000; 92: 1529–31.
  • 5
    Rosenblatt KA, Thomas DB, McTiernan A, Austin MA, Stalsberg H, Stemhagen A, Thompson WD, Curnen MG, Satariano W, Austin DF. Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst 1991; 83: 849–54
  • 6
    Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408: 433–9.
  • 7
    Bartek J, Falck J, Lukas J. CHK2 kinase: a busy messenger. Nat Rev Mol Cell Biol 2001; 2: 877–86.
  • 8
    Chehab NH, Malikzay A, Appel M, Halazonetis TD. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 2000; 14: 278–88
  • 9
    Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell Biol 2000; 1: 179–86.
  • 10
    Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000; 14: 289–300.
  • 11
    Lee JS, Collins KM, Brown AL, Lee CH, Chung JH. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 2000; 404: 201–4.
  • 12
    Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 24;286: 2528–31.
  • 13
    Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomäki K, Nevanlinna H. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 2001; 61: 5718–22.
  • 14
    Meijers-Heijboer H, van Den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002 Published online, DOI:10.1038/ng879; 31: 55–59.
  • 15
    Vahteristo P, Bartkova J, Eerola H, Syrjäkoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomäki K, Heikkilä P, Holli K, Blomqvist C, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002; 71: 432–8.
  • 16
    Syvänen AC. Solid-phase minisequencing as a tool to detect DNA polymorphism. Methods Mol Biol 1998; 98: 291–8.
View Full Article (HTML) Get PDF (50K)